Vaxcyte shares surge as pneumococcal vaccine succeeds in late-stage trial

Vaxcyte said on Monday its experimental ​pneumococcal vaccine generated immune responses comparable to rival vaccines ‌in a late-stage study, sending its shares up 57% in morning trading.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。